An in vitro perspective on the molecular mechanisms underlying mutant huntingtin protein toxicity

Huntington’s disease (HD) is a devastating neurodegenerative disorder whose main hallmark is brain atrophy. However, several peripheral organs are considerably affected and their symptoms may, in fact, manifest before those resulting from brain pathology. HD is of genetic origin and caused by a mutation in the huntingtin gene. The mutated protein has detrimental effects on cell survival, but whether the mutation leads to a gain of toxic function or a loss of function of the altered protein is still highly controversial. Most currently used in vitro models have been designed, to a large extent, to investigate the effects of the aggregation process in neuronal-like cells. However, as the pathology involves several other organs, new in vitro models are critically needed to take into account the deleterious effects of mutant huntingtin in peripheral tissues, and thus to identify new targets that could lead to more effective clinical interventions in the early course of the disease. This review aims to present current in vitro models of HD pathology and to discuss the knowledge that has been gained from these studies as well as the new in vitro tools that have been developed, which should reflect the more global view that we now have of the disease.

[1]  Danielle A. Simmons,et al.  Ferritin accumulation in dystrophic microglia is an early event in the development of Huntington's disease , 2007, Glia.

[2]  N. Wood,et al.  Disruption of Peripheral Circadian Timekeeping in a Mouse Model of Huntington's Disease and Its Restoration by Temporally Scheduled Feeding , 2010, The Journal of Neuroscience.

[3]  Rahul S. Rajan,et al.  Specificity in intracellular protein aggregation and inclusion body formation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  D. Rubinsztein,et al.  Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease. , 2001, Human molecular genetics.

[5]  T. Hansen,et al.  Huntington’s Disease Does Not Appear to Increase the Risk of Diabetes Mellitus , 2009, Journal of neuroendocrinology.

[6]  J. Mandel,et al.  A cellular model that recapitulates major pathogenic steps of Huntington's disease. , 1998, Human molecular genetics.

[7]  F. Squitieri,et al.  Huntingtin fragmentation and increased caspase 3, 8 and 9 activities in lymphoblasts with heterozygous and homozygous Huntington's disease mutation , 2006, Mechanisms of Ageing and Development.

[8]  L. Frati,et al.  DNA instability in replicating Huntington's disease lymphoblasts , 2009, BMC Medical Genetics.

[9]  F. Fornai,et al.  Genotype-, aging-dependent abnormal caspase activity in Huntington disease blood cells , 2011, Journal of Neural Transmission.

[10]  T. Möller,et al.  Distinct neuroinflammatory profile in post-mortem human Huntington's disease , 2009, Neuroreport.

[11]  H. Lehrach,et al.  A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease. , 2004, Molecular cell.

[12]  Richard I. Morimoto,et al.  Polyglutamine protein aggregates are dynamic , 2002, Nature Cell Biology.

[13]  I. Kanazawa,et al.  Caspase activation during apoptotic cell death induced by expanded polyglutamine in N2a cells. , 1999, Neuroreport.

[14]  J. Penney,et al.  Huntingtin localization in brains of normal and Huntington's disease patients , 1997, Annals of neurology.

[15]  A. Tobin,et al.  A cell-based screen for drugs to treat Huntington's disease , 2004, Neurobiology of Disease.

[16]  P. Brundin,et al.  Synaptic dysfunction in Huntington’s disease: a new perspective , 2005, Cellular and Molecular Life Sciences CMLS.

[17]  M. Guillermier,et al.  In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects , 2010, Human molecular genetics.

[18]  M. Hayden,et al.  Predictive testing for persons at risk for homozygosity for CAG expansion in the Huntington disease gene , 2003, Clinical genetics.

[19]  J. Cooper,et al.  Clinical correlates of mitochondrial function in Huntington's disease muscle , 2007, Movement disorders : official journal of the Movement Disorder Society.

[20]  D. Housman Gain of glutamines, gain of function? , 1995, Nature Genetics.

[21]  M. MacDonald,et al.  Amyloid Formation by Mutant Huntingtin: Threshold, Progressivity and Recruitment of Normal Polyglutamine Proteins , 1998, Somatic cell and molecular genetics.

[22]  S. Radford,et al.  Fibril Fragmentation Enhances Amyloid Cytotoxicity*♦ , 2009, The Journal of Biological Chemistry.

[23]  A. Dehejia,et al.  Alpha-synuclein immunoreactivity of huntingtin polyglutamine aggregates in striatum and cortex of Huntington's disease patients and transgenic mouse models , 2000, Neuroscience Letters.

[24]  M. Memo,et al.  Generation of reactive oxygen species by beta amyloid fibrils and oligomers involves different intra/extracellular pathways , 2009, Amino Acids.

[25]  Ji-Yeon Shin,et al.  Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity , 2005, The Journal of cell biology.

[26]  L. Havel,et al.  Preferential accumulation of N-terminal mutant huntingtin in the nuclei of striatal neurons is regulated by phosphorylation. , 2011, Human molecular genetics.

[27]  M. Beal,et al.  Impaired PGC-1alpha function in muscle in Huntington's disease. , 2009, Human molecular genetics.

[28]  M. Beal,et al.  Oxidative damage in Huntington's disease pathogenesis. , 2006, Antioxidants & redox signaling.

[29]  E. Cattaneo,et al.  Cholesterol dysfunction in neurodegenerative diseases: Is Huntington's disease in the list? , 2006, Progress in Neurobiology.

[30]  S. Folstein,et al.  Cognitive and Motor Correlates of Everyday Functioning in Early Huntington's Disease , 1993, The Journal of nervous and mental disease.

[31]  Steven Finkbeiner,et al.  Quantitative Relationships between Huntingtin Levels, Polyglutamine Length, Inclusion Body Formation, and Neuronal Death Provide Novel Insight into Huntington's Disease Molecular Pathogenesis , 2010, The Journal of Neuroscience.

[32]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[33]  Elena Cattaneo,et al.  Loss of normal huntingtin function: new developments in Huntington's disease research , 2001, Trends in Neurosciences.

[34]  Martin Drozda,et al.  Depletion of wild‐type huntingtin in mouse models of neurologic diseases , 2003, Journal of neurochemistry.

[35]  J. O’Kusky,et al.  Toward Understanding the Molecular Pathology of Huntington's Disease , 1997, Brain pathology.

[36]  E. Cattaneo,et al.  Induced pluripotent stem cell lines from Huntington's disease mice undergo neuronal differentiation while showing alterations in the lysosomal pathway , 2012, Neurobiology of Disease.

[37]  A. Delacourte,et al.  Association of corticobasal degeneration and Huntington's disease: Can Tau aggregates protect Huntingtin toxicity? , 2009, Movement disorders : official journal of the Movement Disorder Society.

[38]  Erich E Wanker,et al.  The hunt for huntingtin function: interaction partners tell many different stories. , 2003, Trends in biochemical sciences.

[39]  S. Podolsky,et al.  Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. , 1977, Gerontology.

[40]  Andreas Matouschek,et al.  Inefficient degradation of truncated polyglutamine proteins by the proteasome , 2004, The EMBO journal.

[41]  Dimitri Krainc,et al.  Transcriptional Repression of PGC-1α by Mutant Huntingtin Leads to Mitochondrial Dysfunction and Neurodegeneration , 2006, Cell.

[42]  S. Zeitlin,et al.  Deletion of the triplet repeat encoding polyglutamine within the mouse Huntington's disease gene results in subtle behavioral/motor phenotypes in vivo and elevated levels of ATP with cellular senescence in vitro. , 2006, Human molecular genetics.

[43]  A. Hackam,et al.  Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates , 1998, Nature Genetics.

[44]  Peter Breuer,et al.  Cellular toxicity of polyglutamine expansion proteins: mechanism of transcription factor deactivation. , 2004, Molecular cell.

[45]  George Q. Daley,et al.  Disease-Specific Induced Pluripotent Stem Cells , 2008, Cell.

[46]  J. Marsh,et al.  A two-step path to inclusion formation of huntingtin peptides revealed by number and brightness analysis. , 2010, Biophysical journal.

[47]  C. Ross,et al.  Inducible PC12 cell model of Huntington's disease shows toxicity and decreased histone acetylation , 2003, Neuroreport.

[48]  F. Giorgini,et al.  Connecting the dots in Huntington's disease with protein interaction networks , 2005, Genome Biology.

[49]  Emmanuel Brouillet,et al.  Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment , 2005, Neurobiology of Disease.

[50]  L Gan,et al.  HIP1 Functions in Clathrin-mediated Endocytosis through Binding to Clathrin and Adaptor Protein 2* , 2001, The Journal of Biological Chemistry.

[51]  A. Morton,et al.  Microglia density decreases with age in a mouse model of Huntington's disease , 2003, Glia.

[52]  J. Caviston,et al.  Huntingtin as an essential integrator of intracellular vesicular trafficking. , 2009, Trends in cell biology.

[53]  T. Outeiro,et al.  α‐Synuclein modifies huntingtin aggregation in living cells , 2012, FEBS letters.

[54]  M. Hayden,et al.  Phenotypic abnormalities in the YAC128 mouse model of Huntington disease are penetrant on multiple genetic backgrounds and modulated by strain , 2007, Neurobiology of Disease.

[55]  Xingshun Xu,et al.  Loss of huntingtin-associated protein 1 impairs insulin secretion from pancreatic β-cells , 2011, Cellular and Molecular Life Sciences.

[56]  M. H. Polymeropoulos,et al.  Alpha synuclein in neurodegenerative disorders: Murderer or accomplice? , 1998, Nature Medicine.

[57]  He Li,et al.  Inhibition of neurite outgrowth and promotion of cell death by cytoplasmic soluble mutant huntingtin stably transfected in mouse neuroblastoma cells , 2008, Neuroscience Letters.

[58]  D. Rubinsztein,et al.  Alpha-synuclein overexpression promotes aggregation of mutant huntingtin. , 2000, The Biochemical journal.

[59]  Hans Lehrach,et al.  Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo , 1997, Cell.

[60]  A. Sarmento-Ribeiro,et al.  Evidence of apoptosis and mitochondrial abnormalities in peripheral blood cells of Huntington's disease patients. , 2008, Biochemical and biophysical research communications.

[61]  J. Lucas,et al.  Alpha-synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington ́ s disease , 2011 .

[62]  A. Messer,et al.  Instability of the CAG repeat in immortalized fibroblast cell cultures from Huntington's Disease transgenic mice 1 Published on the World Wide Web on 15 April 1999. 1 , 1999, Brain Research.

[63]  Inducing huntingtin inclusion formation in primary neuronal cell culture and in vivo by high‐capacity adenoviral vectors expressing truncated and full‐length huntingtin with polyglutamine expansion , 2008, The journal of gene medicine.

[64]  Cheng Song,et al.  Expression of Full-length Polyglutamine-expanded Huntingtin Disrupts Growth Factor Receptor Signaling in Rat Pheochromocytoma (PC12) Cells* , 2002, The Journal of Biological Chemistry.

[65]  D. Housman,et al.  The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[66]  Alexander Gerhard,et al.  Microglial activation in presymptomatic Huntington's disease gene carriers. , 2005, Brain : a journal of neurology.

[67]  M. Yoshimoto,et al.  NACP, the precursor protein of the non-amyloid beta/A4 protein (A beta) component of Alzheimer disease amyloid, binds A beta and stimulates A beta aggregation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[68]  L. Kaltenbach,et al.  Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons , 2012, Neurobiology of Aging.

[69]  Rama S. Verma,et al.  An improved protocol for primary culture of cardiomyocyte from neonatal mice , 2008, In Vitro Cellular & Developmental Biology - Animal.

[70]  Suzanne Tydlacka,et al.  Differential Activities of the Ubiquitin–Proteasome System in Neurons versus Glia May Account for the Preferential Accumulation of Misfolded Proteins in Neurons , 2008, The Journal of Neuroscience.

[71]  Yen F. Tai,et al.  Imaging microglial activation in Huntington's disease , 2007, Brain Research Bulletin.

[72]  M. Hayden,et al.  A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease , 2008, The Journal of experimental medicine.

[73]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[74]  J. Mazzola,et al.  Reduction of glyceraldehyde‐3‐phosphate dehydrogenase activity in Alzheimer's disease and in Huntington's disease fibroblasts , 2001, Journal of neurochemistry.

[75]  S. Finkbeiner,et al.  Serines 13 and 16 Are Critical Determinants of Full-Length Human Mutant Huntingtin Induced Disease Pathogenesis in HD Mice , 2009, Neuron.

[76]  Hiroshi Kimura,et al.  Cytosolic chaperonin prevents polyglutamine toxicity with altering the aggregation state , 2006, Nature Cell Biology.

[77]  A. Hackam,et al.  Evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease in cell culture and in transgenic mice expressing mutant huntingtin. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[78]  M. Beal,et al.  Hunting-ton for New Proteases: MMPs as the New Target? , 2010, Neuron.

[79]  D. Rubinsztein,et al.  Microtubule disruption inhibits autophagosome-lysosome fusion: implications for studying the roles of aggresomes in polyglutamine diseases. , 2004, The international journal of biochemistry & cell biology.

[80]  R. Schwarcz,et al.  Histone Deacetylase Inhibition Modulates Kynurenine Pathway Activation in Yeast, Microglia, and Mice Expressing a Mutant Huntingtin Fragment* , 2008, Journal of Biological Chemistry.

[81]  Andrew F Hill,et al.  Tracking Mutant Huntingtin Aggregation Kinetics in Cells Reveals Three Major Populations That Include an Invariant Oligomer Pool* , 2010, The Journal of Biological Chemistry.

[82]  J. Lucas,et al.  α-Synuclein accumulates in huntingtin inclusions but forms independent filaments and its deficiency attenuates early phenotype in a mouse model of Huntington's disease. , 2012, Human molecular genetics.

[83]  K. Wilkinson,et al.  Modulating huntingtin half‐life alters polyglutamine‐dependent aggregate formation and cell toxicity , 2004, Journal of neurochemistry.

[84]  Z. Qin,et al.  Rapamycin prevents the mutant huntingtin-suppressed GLT-1 expression in cultured astrocytes , 2012, Acta Pharmacologica Sinica.

[85]  D. Altschuh,et al.  Huntingtin affinity for partners is not changed by polyglutamine length: aggregation itself triggers aberrant interactions. , 2011, Human molecular genetics.

[86]  Christopher A. Ross,et al.  Huntingtin Spheroids and Protofibrils as Precursors in Polyglutamine Fibrilization* , 2002, The Journal of Biological Chemistry.

[87]  P. Mcgeer,et al.  Optineurin in Huntington's disease intranuclear inclusions , 2012, Neuroscience Letters.

[88]  S. Hersch,et al.  Interaction of Huntingtin-Associated Protein with Dynactin P150Glued , 1998, The Journal of Neuroscience.

[89]  E. Seeberg,et al.  Mutant Huntingtin Impairs Axonal Trafficking in Mammalian Neurons In Vivo and In Vitro , 2004, Molecular and Cellular Biology.

[90]  P. Reddy,et al.  Polyglutamine-expanded Huntingtin Promotes Sensitization of N-Methyl-d-aspartate Receptors via Post-synaptic Density 95* , 2001, The Journal of Biological Chemistry.

[91]  Christopher A Ross,et al.  A structure-based analysis of huntingtin mutant polyglutamine aggregation and toxicity: evidence for a compact beta-sheet structure. , 2005, Human molecular genetics.

[92]  D. Irimia,et al.  Multiple phenotypes in Huntington disease mouse neural stem cells , 2012, Molecular and Cellular Neuroscience.

[93]  M. Chiang,et al.  The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease. , 2011, Biochimica et biophysica acta.

[94]  F. Fornai,et al.  Abnormal morphology of peripheral cell tissues from patients with Huntington disease , 2009, Journal of Neural Transmission.

[95]  J. Cooper,et al.  Inclusion formation in Huntington's disease R6/2 mouse muscle cultures , 2003, Journal of neurochemistry.

[96]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[97]  Elena Cattaneo,et al.  Normal huntingtin function: an alternative approach to Huntington's disease , 2005, Nature Reviews Neuroscience.

[98]  K. Rezvani,et al.  Modeling Pathogenesis of Huntington’s Disease with Inducible Neuroprogenitor Cells , 2011, Cellular and Molecular Neurobiology.

[99]  R. Richards,et al.  Selective neuronal requirement for huntingtin in the developing zebrafish , 2009, Human molecular genetics.

[100]  M. Hayden,et al.  Testicular degeneration in Huntington disease , 2007, Neurobiology of Disease.

[101]  Thomas H Gillingwater,et al.  Progressive abnormalities in skeletal muscle and neuromuscular junctions of transgenic mice expressing the Huntington's disease mutation , 2004, The European journal of neuroscience.

[102]  Wenzhen Duan,et al.  Peroxisome-Proliferator-Activated Receptor Gamma Coactivator 1 α Contributes to Dysmyelination in Experimental Models of Huntington's Disease , 2011, The Journal of Neuroscience.

[103]  M. Russo,et al.  Increased apoptosis, huntingtin inclusions and altered differentiation in muscle cell cultures from Huntington's disease subjects , 2006, Cell Death and Differentiation.

[104]  A. Wyttenbach,et al.  Neurotoxic protein oligomerisation associated with polyglutamine diseases , 2010, Acta Neuropathologica.

[105]  K Dane Wittrup,et al.  Stochastic kinetics of intracellular huntingtin aggregate formation , 2006, Nature chemical biology.

[106]  G. Bates,et al.  Sensitive biochemical aggregate detection reveals aggregation onset before symptom development in cellular and murine models of Huntington’s disease , 2007, Journal of neurochemistry.

[107]  M. Hayden,et al.  The likelihood of being affected with Huntington disease by a particular age, for a specific CAG size. , 1997, American journal of human genetics.

[108]  Chuan-en Wang,et al.  Mutant Huntingtin in Glial Cells Exacerbates Neurological Symptoms of Huntington Disease Mice* , 2010, The Journal of Biological Chemistry.

[109]  M. Sherman,et al.  Characterization of Proteins Associated with Polyglutamine Aggregates , 2007, Prion.

[110]  K. Varani,et al.  Aberrant A2A receptor function in peripheral blood cells in Huntington's disease , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[111]  Jun-chao Wu,et al.  Expression of mutant N-terminal huntingtin fragment (htt552-100Q) in astrocytes suppresses the secretion of BDNF , 2012, Brain Research.

[112]  Alexander Hammers,et al.  A systematic comparison of kinetic modelling methods generating parametric maps for [11C]-(R)-PK11195 , 2007, NeuroImage.

[113]  D. Rubinsztein,et al.  Wild type huntingtin reduces the cellular toxicity of mutant huntingtin in mammalian cell models of Huntington's disease , 2001, Journal of medical genetics.

[114]  Denis Soulet,et al.  Mutant huntingtin interacts with {beta}-tubulin and disrupts vesicular transport and insulin secretion. , 2009, Human molecular genetics.

[115]  D. Rubinsztein,et al.  Deletion of the Huntingtin Polyglutamine Stretch Enhances Neuronal Autophagy and Longevity in Mice , 2010, PLoS genetics.

[116]  D. Dickson,et al.  Expanded-Polyglutamine Huntingtin Protein Suppresses the Secretion and Production of a Chemokine (CCL5/RANTES) by Astrocytes , 2008, The Journal of Neuroscience.

[117]  A. Morton,et al.  Time-lapse analysis of aggregate formation in an inducible PC12 cell model of Huntington's disease reveals time-dependent aggregate formation that transiently delays cell death , 2008, Brain Research Bulletin.

[118]  M. Hendrix,et al.  Tissue culture of epithelial cells from esophageal specialized columnar epithelium (Barrett's esophagus) , 1992, Digestive Diseases and Sciences.

[119]  Z. Qin,et al.  Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[120]  R. Wetzel,et al.  Polyglutamine aggregation behavior in vitro supports a recruitment mechanism of cytotoxicity. , 2001, Journal of molecular biology.

[121]  Chuan-en Wang,et al.  Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms , 2009, Proceedings of the National Academy of Sciences.

[122]  T. Hortobágyi,et al.  Optineurin inclusions occur in a minority of TDP-43 positive ALS and FTLD-TDP cases and are rarely observed in other neurodegenerative disorders , 2011, Acta Neuropathologica.

[123]  S. Yamanaka,et al.  Recent Stem Cell Advances: Induced Pluripotent Stem Cells for Disease Modeling and Stem Cell–Based Regeneration , 2010, Circulation.

[124]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[125]  Steve D. M. Brown,et al.  α-Synuclein levels modulate Huntington's disease in mice. , 2012, Human molecular genetics.

[126]  M. Hayden,et al.  Huntingtin is required for normal hematopoiesis. , 2000, Human molecular genetics.

[127]  E. Cattaneo,et al.  Role of brain-derived neurotrophic factor in Huntington's disease , 2007, Progress in Neurobiology.

[128]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[129]  S. Floresco,et al.  Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes , 1995, Cell.

[130]  D. Rubinsztein,et al.  Transcriptional abnormalities in Huntington disease. , 2003, Trends in genetics : TIG.

[131]  David Blum,et al.  Adenosine receptors and Huntington's disease: implications for pathogenesis and therapeutics , 2003, The Lancet Neurology.

[132]  L. K. Baker,et al.  Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability* , 2002, The Journal of Biological Chemistry.

[133]  L. Thompson,et al.  Severe ultrastructural mitochondrial changes in lymphoblasts homozygous for Huntington disease mutation , 2006, Mechanisms of Ageing and Development.

[134]  F. Cicchetti,et al.  The role of immunity in Huntington's disease , 2011, Molecular Psychiatry.

[135]  A. Hackam,et al.  In vitro evidence for both the nucleus and cytoplasm as subcellular sites of pathogenesis in Huntington's disease. , 1999, Human molecular genetics.

[136]  K. Hoyt,et al.  Cardiac dysfunction in the R6/2 mouse model of Huntington’s disease , 2007, Neurobiology of Disease.

[137]  G. Bates,et al.  Huntingtin aggregation and toxicity in Huntington's disease , 2003, The Lancet.

[138]  Fumiaki Tanaka,et al.  Aggresomes protect cells by enhancing the degradation of toxic polyglutamine-containing protein. , 2003, Human molecular genetics.

[139]  M. MacDonald,et al.  Interaction of normal and expanded CAG repeat sizes influences age at onset of Huntington disease , 2003, American journal of medical genetics. Part A.

[140]  Blair R. Leavitt,et al.  Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.

[141]  C. Ross,et al.  Huntington disease: pathogenesis, biomarkers, and approaches to experimental therapeutics. , 2009, Parkinsonism & related disorders.

[142]  Xiao-Bo Sun,et al.  Overexpression of F(0)F(1)-ATP synthase alpha suppresses mutant huntingtin aggregation and toxicity in vitro. , 2009, Biochemical and biophysical research communications.

[143]  S. W. Davies,et al.  Formation of polyglutamine inclusions in non-CNS tissue. , 1999, Human molecular genetics.

[144]  M. Hayden,et al.  Wild‐type huntingtin protects neurons from excitotoxicity , 2006, Journal of neurochemistry.

[145]  Austin G Smith,et al.  The first reported generation of several induced pluripotent stem cell lines from homozygous and heterozygous Huntington's disease patients demonstrates mutation related enhanced lysosomal activity , 2012, Neurobiology of Disease.

[146]  P. Muchowski Protein Misfolding, Amyloid Formation, and Neurodegeneration A Critical Role for Molecular Chaperones? , 2002, Neuron.

[147]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[148]  S. Zeitlin,et al.  Expression of the Huntingtin-associated protein 1 gene in the developing and adult mouse , 2000, Neuroscience Letters.

[149]  L. Raymond,et al.  Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin , 2006, Cell.

[150]  G. Bates,et al.  Formation of Polyglutamine Inclusions in a Wide Range of Non-CNS Tissues in the HdhQ150 Knock-In Mouse Model of Huntington's Disease , 2009, PloS one.

[151]  E. Cattaneo,et al.  Modeling huntington’s disease in cells, flies, and mice , 2001, Molecular Neurobiology.

[152]  Osamu Onodera,et al.  Soluble polyglutamine oligomers formed prior to inclusion body formation are cytotoxic. , 2008, Human molecular genetics.

[153]  V. Silani,et al.  Huntington's disease: The current state of research with peripheral tissues , 2009, Experimental Neurology.

[154]  M. Pennuto,et al.  Post-translational modifications of expanded polyglutamine proteins: impact on neurotoxicity. , 2009, Human Molecular Genetics.

[155]  J. Olson,et al.  Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses. , 2002, Human molecular genetics.

[156]  P. Paganetti,et al.  Inducible mutant huntingtin expression in HN10 cells reproduces Huntington's disease-like neuronal dysfunction , 2009, Molecular Neurodegeneration.

[157]  Jiandie D. Lin,et al.  Suppression of Reactive Oxygen Species and Neurodegeneration by the PGC-1 Transcriptional Coactivators , 2006, Cell.

[158]  E. Kavanagh,et al.  Caspase signalling controls microglia activation and neurotoxicity , 2011, Nature.